Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pazopanib in Renal Cell Carcinoma
NCT01361113Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jun 2011
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Objective Response Rate at 8 weeks. Started Jun 2011; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01361113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01361113.